Inovio Pharmaceuticals Inc. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones

2025.11.18 22:27

I'm PortAI, I can summarize articles.

Inovio Pharmaceuticals Inc. (INO) stock fell 4.55% to $1.89 on Tuesday, underperforming compared to competitors like Johnson & Johnson and Pfizer, which saw gains. This marked the second consecutive day of losses for Inovio, with the stock closing 59% below its 52-week high. The trading volume matched its 50-day average. The NASDAQ and Dow Jones also experienced declines.

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Inovio Pharmaceuticals Inc. (INO) shed 4.55% to $1.89 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index falling 1.21% to 22,432.85 and Dow Jones Industrial Average falling 1.07% to 46,091.74. This was the stock's second consecutive day of losses. Inovio Pharmaceuticals Inc. closed 59.00% below its 52-week high of $4.61, which the company reached on December 3rd. The stock underperformed when compared to some of its competitors Tuesday, as Johnson & Johnson (JNJ) rose 0.21% to $200.00, Statera Biopharma Inc. (STAB) remained unchanged, and Pfizer Inc. (PFE) rose 1.48% to $25.45. Trading volume (1.2 M) eclipsed its 50-day average volume of 1.2 M. Data source: Dow Jones Market Data, FactSet. Data compiled November 18, 2025. This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. (END) Dow Jones Newswires 11-18-25 1727ET